Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized trial of subcutaneous anakinra in Japanese patients with Still's disease
jRCT2031220222Phase 3Completed
- Sponsor
- Sobi
- Start
- Apr 2023
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic juvenile idiopathic arthritis (SJIA) and adult-onset Still's disease (AOSD) comparing Anakinra with Placebo (2 arms). Primary endpoint: ACR30 response with absence of fever at Week 2. Started Apr 2023; status: completed.
02
Drugs
anakinra
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)adult-onset Still's disease (AOSD)
Beyond the preview
Go deeper on jRCT2031220222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220222.